A whale with a lot of money to spend has taken a noticeably bearish stance on Reata Pharmaceuticals.
Looking at options history for Reata Pharmaceuticals RETA we detected 22 strange trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 81% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,316,804 and 8, calls, for a total amount of $412,420.
What's The Price Target?
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $65.0 for Reata Pharmaceuticals over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Reata Pharmaceuticals's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Reata Pharmaceuticals's whale activity within a strike price range from $15.0 to $65.0 in the last 30 days.
Reata Pharmaceuticals Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| RETA | PUT | SWEEP | BEARISH | 03/17/23 | $25.00 | $465.0K | 4.2K | 1.1K |
| RETA | PUT | SWEEP | BEARISH | 03/17/23 | $50.00 | $280.0K | 4.3K | 134 |
| RETA | CALL | SWEEP | NEUTRAL | 03/17/23 | $35.00 | $135.7K | 882 | 574 |
| RETA | PUT | SWEEP | BULLISH | 03/17/23 | $40.00 | $110.9K | 2.5K | 268 |
| RETA | PUT | SWEEP | BEARISH | 08/18/23 | $65.00 | $100.0K | 2 | 35 |
Where Is Reata Pharmaceuticals Standing Right Now?
- With a volume of 6,282,246, the price of RETA is down -34.73% at $29.05.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 11 days.
What The Experts Say On Reata Pharmaceuticals:
- Goldman Sachs has decided to maintain their Buy rating on Reata Pharmaceuticals, which currently sits at a price target of $117.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Reata Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
